Sir,
In the 20 October 2003 issue, Aparicio et al (2003) reported about 66 patients with metastasic colorectal cancer aged from 75 to 88 (median, 78) treated with oxaliplatin or irinotecan in combination with either 5-fluorouracil or raltitrexed. The authors state on the feasibility of these regimens in the elderly population. The first point is the limited recruitment by 12 centres during more than 3 years, suggesting highly selected population. It would have been interesting to estimate the proportion of patients receiving no chemotherapy. The main point is the high grade III or IV toxicity rate of 42%. Given the prognosis and cost of these drugs, is this acceptable? Although efficacy is a major goal in some situations including candidates to metastasectomy or parents of young children, chemotherapy remains palliative in nearly all cases. Significant increased toxicity has previously been found in patients aged over 65 years in two phase II study of irinotecan (Rougier et al, 1997; Rothenberg et al, 1999). Increased toxicity is logically observed in elderly patients given numerous pharmacokinetic changes, including loss of total body water, increased total body fat, or decreased albumin (Wallace and Verbeck, 1983). Oxaliplatin is intensively bound on the erythrocytes (Pendyala and Creaven, 1993). The albumin protein binding for oxaliplatin and SN-38, the active metabolite of irinotecan is greater than 90%. Thus, the volume of distribution may be also increased by anaemia or hypoalbuminaemia. The glomerular filtration rate progressively declines by about 1% each year after the age of 40 years (Evers et al, 1995). Thus, dose adaptation of drugs with renal elimination has been proposed in case of creatinine clearance lower than 60 ml min−1 (Kintzel and Dorr, 1995). The mean creatinine clearance was about 57 ml min−1 in the present study. Polypharmacy also is a major concern. Certain treatments of comorbid illnesses may interfere with chemotherapy, in particular for cytochrome P-450 enzyme or conjugation reactions. Irinotecan is extensively metabolised by the cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 (Santos et al, 2000). For example, CYP3A4 can be induced by carbamazepin or phenytoin and inhibited by macrolides or antifungal imidazoles (Balis, 1986). Numerous drugs such as warfarin, phenytoin or salicylates may displace chemotherapeutic agents from albumin binding sites (Spina and Scordo, 2002). In other words, standard full-dose regimen represents overdosage in a wide fraction of this population. Hepatic impairment due to liver involvement might be a particular concern. Bilirubin might compete with chemotherapeutic agents for albumin binding. Significant elevations in transaminases have been reported under raltitrexed, particularly in case of hepatic metastases or abnormal baseline transaminases levels (Cocconi et al, 1998). The liver intervenes by many aspects in the metabolism of irinotecan and SN38, implicating the cytochromes, glucuro-conjugation by UDP-glucuronosyltransferase 1A1 (UGT1A1) and enterohepatic cycling, resulting in wide interpatient variability (Rivory, 2000). High bilirubin and alkaline phosphate levels are associated with toxicity (Raymond et al, 2002). Severe toxicity also has been observed in patients with unconjugated hyperbilirubinaemia due to UGT1A1 deficiency (Wasserman et al, 1997) encountered in Gilbert's syndrome (5% of the population). Although the present study demonstrates significant efficacy in elderly patients, chemotherapy must be adapted to the diversity of the elderly population. In line with this, certain measures potentially could decrease toxicity such as the adaptation of comedications or correction of anaemia and hypoalbuminaemia. Alkalisation might prevent irinotecan-induced diarrhoea by orientating the intestinal metabolism of SN-38 towards carboxylate form (Ikegami et al, 2002).
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aparicio T, Desramé J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Eznfis J, Artru P, Mabro M, Dominguez S (2003) Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89: 1439–1444
Balis FM (1986) Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 11: 223–235
Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM, on behalf of the Tomudex Colorectal Cancer Study Group (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16: 2943–2952
Evers BM, Townsend CM, Thompson JC (1995) Organ physiology of ageing. Surg Clin North Am 74: 23–39
Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B (2002) Intestinal alkalisation as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62: 179–187
Kintzel PE, Dorr RT (1995) Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 21: 33–64
Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970–5976
Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Vernillet L, Jacques C, Gatineau M, Ducreux M, Armand JP (2002) Dosage adjustement and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 20: 4303–4312
Rivory L (2000) Metabolism of CPT-11. Ann NY Acad Sci 922: 205–215
Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer Jr CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85: 786–795
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251–260
Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6: 2012–2020
Spina E, Scordo MG (2002) Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19: 299–320
Wallace SM, Verbeck RK (1983) Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 12: 41–72
Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E (1997) Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 8: 1049–1051
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Alliot, C., Barrios, M. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 90, 2050–2051 (2004). https://doi.org/10.1038/sj.bjc.6601805
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6601805